WinstonWınston
Back
Medacta Group S.A. logo

Medacta Group S.A.

MOVE.SW
69
Medical - Specialties · Healthcare
Also trades as: 0A05.L
Exchange
SIX Swiss Exchange
Winston Score
69
Winston is curious
A decent business — some strong pillars, some weaker.
Data as of Aug 23, 2026 · filings through Dec 31, 2025
How the score breaks down
Quality
Strong
Growth
Strong
Cash Flow
Strong
Stability
Exceptional
Valuation
Strong
Dividends
Weak

Winston Score History

The full picture

Medacta Group is a Swiss medical device company that makes artificial joints and surgical tools used in hospitals around the world. Its main products are replacement implants for knees, hips, shoulders, and spines — the kind surgeons use when a patient's natural joint wears out or gets damaged. Medacta also sells a surgical training system called MyKnee and MyShoulder, which uses patient scans to help surgeons plan and perform more precise operations.

The company earns money by selling its implants and related instruments directly to hospitals and surgical centers, mostly through its own sales force rather than third-party distributors. Medacta operates primarily in Europe, the United States, and Australia, with the U.S. market being a key growth target. Its main competitive edge comes from its surgeon education programs and proprietary surgical techniques, which create loyalty among doctors who train on its systems. The biggest risk is competing against much larger rivals like Zimmer Biomet and Stryker, which have far greater resources and established hospital relationships.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+12.7% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+2.9% YoY

YoY Growth Rate

Slow EPS growth

Insider Activity

69.9%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

CHF 35M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

Medacta Group S.A. is a rare growth stock that's already generating positive cash flow while growing at 13%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
65.8%
Premium pricing power — 65.8% gross margin
Profit after running costs
Operating Margin
12.2%
Healthy — 12.2% operating margin
Return on the money invested
ROCE
17.5%
Strong — 17.5% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+15.9%
Fast-growing sales (+15.9% YoY)
Profit growth
EPS YoY
+31.8%
Earnings growing fast (+31.8% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
159%
Turns 159% of profit into real cash
Spare cash per sale
FCF Margin
4.3%
Thin free cash flow (4.3%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.45
Conservative — low debt load (0.45)
Covers its interest
Interest Cover
16.87x
Comfortably covers interest (16.9x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
29.2x
no trend
Growth-priced — P/E 29.2

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year
P/E vs Forward
+9.3
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (29.2 → 19.9)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
0.83%
no trend
Small dividend — 0.83% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record
Dividend Growth
N/A
no trend
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial